Navigating the Complexity of Melanoma Care: A Case-Based Debate
This dynamic, case-based debate brings together melanoma specialists to examine first-line treatment options, sequencing in BRAF-mutant disease, and the integration of central nervous system (CNS)-directed therapy for brain metastases. Designed for oncology professionals, the session highlights where evidence is strongest, where data are evolving, and how to personalize decisions amid competing, guideline-supported options.
Round 1
Treatment for Patient Case 1
The debate opens with a case exploring first-line treatment for BRAF wild-type metastatic melanoma, weighing the long-term benefits of ipilimumab+nivolumab against the tolerability of nivolumab+relatlimab.
Round 2
Treatment for Patient Case 2
In the second round, panelists debate whether patients with BRAF-mutant melanoma should start with targeted therapy or combination immunotherapy, weighing durability of response, toxicity, and sequencing strategies.
Round 3
Treatment for Patient Case 3
The panel discusses optimal initial management of brain metastases in the third round, comparing evidence for combination immunotherapy with the role of CNS-directed therapy.
© 2025 HMP Global. All Rights Reserved.
This is a non-CME activity. Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
